Upregulation of long noncoding RNA XIST has anticancer effects on ovarian cancer through sponging miR-106a

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Ovarian cancer (OC) is a highly malignant tumor with poorly defined therapeutic targets.
• The long non-coding RNA XIST has been implicated in cancer, but its specific role in OC requires further elucidation.

Purpose of the Study:

• To investigate the functional role and therapeutic potential of XIST in ovarian cancer.
• To determine the interaction between XIST and microRNA-106a (miR-106a) in OC development.

Main Methods:

• Quantitative real-time PCR (RT-qPCR) to assess XIST and miR-106a expression levels.
• In vitro assays including flow cytometry, colony formation, and CCK-8 to evaluate cell apoptosis and proliferation.
• Bioinformatics analysis, dual-luciferase reporter assays, and RNA pull-down assays to confirm XIST-miR-106a interaction.
• In vivo studies using OC xenograft nude mice to assess tumor growth.

Main Results:

• Ovarian cancer tissues and cell lines showed significantly lower XIST expression and higher miR-106a expression compared to normal controls.
• Upregulation of XIST inhibited proliferation and promoted apoptosis in OC cell lines (OVCAR3 and CAOV3).
• XIST directly targeted miR-106a, and overexpression of miR-106a counteracted the tumor-suppressive effects of XIST.
• In vivo experiments confirmed that XIST decelerated tumor growth, an effect reversed by miR-106a.

Conclusions:

• XIST acts as a tumor suppressor in ovarian cancer by inhibiting cell proliferation and promoting apoptosis.
• The mechanism involves XIST sponging miR-106a, thereby regulating OC development.
• XIST holds potential as a therapeutic target for ovarian cancer treatment.